ReviewAntimicrobial stewardship & healthcare epidemiology : ASHE2022
It is complicated: Potential short- and long-term impact of coronavirus disease 2019 (COVID-19) on antimicrobial resistance-An expert review.
Review in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Lessons From the Coronavirus Disease 2019 Pandemic: Implications for Antimicrobial Stewardship for COVID-19 Management.Journal of Korean medical science · 2026Review
- Analysis of multidrug-resistant Gram-negative pathogens (MRGN) in different areas of the healthcare system and their significance in the outpatient sector.GMS infectious diseases · 2026Article
- MDR Bacteremia in the Critically Ill During COVID-19: The MARTINI Study.Pathogens (Basel, Switzerland) · 2025Observational
- A shared approach to managing urinary tract infections in nursing homes improved perceived care quality, workload, and collaboration - a qualitative study.Scandinavian journal of primary health care · 2025Article
- Kinetic Patterns of Antibiotic Consumption in German Acute Care Hospitals from 2017 to 2023.Antibiotics (Basel, Switzerland) · 2025Article
- A Change in Nosocomial Infections among Surgical ICU Patients in the COVID-19 Era and MALDI-TOF Mass Spectrometry-A Cross-Sectional Study.Microorganisms · 2024Article
- Impact of the COVID-19 pandemic on extended-spectrum β-lactamase producing Escherichia coli in urinary tract and blood stream infections: results from a nationwide surveillance network, Finland, 2018 to 2022.Antimicrobial resistance and infection control · 2024Article
- Post-Coronavirus Disease 2019 Pandemic Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Impact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Prevalence and Antimicrobial Resistance Patterns of Hospital Acquired Infections through the COVID-19 Pandemic: Real-Word Data from a Tertiary Urological Centre.Journal of clinical medicine · 2023Article
- Antibiotic resistance and the COVID-19 pandemic: A dual crisis with complex challenges in LMICs.Health science reports · 2023Article
- Article
- Impacts of the COVID-19 pandemic on antimicrobial use in companion animals in an academic veterinary hospital in North Carolina.Zoonoses and public health · 2023Article
- Use of antimicrobials during the COVID-19 pandemic: A qualitative study among stakeholders in Nepal.PLOS global public health · 2023Article
- Solution characterization of the dynamic conjugative entry exclusion protein TraG.Structural dynamics (Melville, N.Y.) · 2022Article
- Comment on: Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19).The Journal of antimicrobial chemotherapy · 2022Article
- Ten ways to make the most of World Antimicrobial Awareness Week.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As of December 2021, the coronavirus disease 2019 (COVID-19) pandemic has claimed millions of deaths and caused disruptions in health systems around the world. The short- and long-term effects of COVID-19 on antimicrobial resistance (AMR), which was already a global threat before the pandemic, are manifold and complex. In this expert review, we summarize how COVID-19 might be affecting AMR in the short term (by influencing the key determinants antibiotic use, infection control practices and international/local mobility) and which additional factors might play a role in the long term. Whereas reduced outpatient antibiotic use in high-income countries, increased awareness for hand hygiene, and reduced mobility have likely mitigated the emergence and spread of AMR in the short term, factors such as overuse of antibiotics in COVID-19 patients, shortage of personal protective equipment, lack of qualified healthcare staff, and patient overcrowding have presumably facilitated its propagation. Unsurprisingly, international and national AMR surveillance data for 2020 show ambiguous trends. Although disruptions in antibiotic stewardship programs, AMR surveillance and research might promote the spread of AMR, other developments could prove beneficial to the cause in the long term. These factors include the increased public awareness for infectious diseases and infection control issues, the strengthening of the One Health perspective as outlined by the Centers for Disease Control and Prevention, and the unprecedented number of international research collaborations and platforms. These factors could even serve as leverage and provide opportunities to better combat AMR in the future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.